Ranking Muscle Relaxants by Strength
There is no clinically meaningful difference in efficacy between muscle relaxants—they all perform similarly to placebo for musculoskeletal pain, so "strength" rankings are not evidence-based for therapeutic decision-making. 1
Critical Evidence on Muscle Relaxant Efficacy
The most recent high-quality evidence from 2022 analyzed seven skeletal muscle relaxants (baclofen, metaxalone, tizanidine, diazepam, orphenadrine, methocarbamol, and cyclobenzaprine) in patients with acute low back pain. None showed statistically significant superiority over placebo when combined with NSAIDs 1. The mean improvement scores were:
- Tizanidine: 11.5 (95% CI 9.5-13.4)
- Diazepam: 11.1 (95% CI 9-13.2)
- Baclofen: 10.6 (95% CI 8.6-12.7)
- Placebo: 10.5 (95% CI 9.5-11.5)
- Metaxalone: 10.3 (95% CI 8.1-12.4)
- Cyclobenzaprine: 10.1 (95% CI 8.3-12)
- Orphenadrine: 9.5 (95% CI 7.4-11.5)
- Methocarbamol: 8.1 (95% CI 6.1-10.1)
These differences are not clinically or statistically significant 1.
Neuromuscular Blocking Agents (Anesthesia Context)
If you're asking about neuromuscular blocking agents used in anesthesia (a completely different class), the potency ranking from clinical pharmacology data is 2:
By Potency (Lowest Dose Required):
- Doxacurium - Most potent (37-80 mcg/kg)
- Pipecuronium - (45-80 mcg/kg)
- Vecuronium/Atracurium - Intermediate
- Rocuronium - (500-600 mcg/kg for rapid onset)
- Mivacurium - Least potent (100-250 mcg/kg)
Cisatracurium is more potent than atracurium among the benzylisoquinoline class 3.
By Speed of Onset:
- Rocuronium (Org 9426): Fastest (~1.5 min at 0.5-0.6 mg/kg) 2
- Mivacurium: 2-4 min 2
- Pipecuronium: 3-6 min 2
- Doxacurium: Slowest (3.5-10 min) 2
Clinical Pitfalls
Common mistake: Assuming "stronger" muscle relaxants provide better pain relief. The 2022 evidence shows this is false—cyclobenzaprine actually had more adverse effects than placebo without superior efficacy 1.
Sedation is not efficacy: Cyclobenzaprine's sedative effects come from potent H1 receptor antagonism, not muscle relaxation 4. Drowsiness occurs in >30% of patients but doesn't correlate with therapeutic benefit.
Context matters: The guidelines provided 3 address neuromuscular blocking agents for anesthesia (rocuronium, cisatracurium, atracurium), which are fundamentally different from oral skeletal muscle relaxants prescribed for back pain.
Practical Recommendation
For musculoskeletal pain, avoid muscle relaxants entirely or use the least sedating option if required, as none demonstrate superiority over placebo and all carry sedation risk 1. Focus on NSAIDs (with appropriate GI/renal precautions) and non-pharmacologic interventions instead.